The core operating loss (excluding one-time Bayer revenue) remains substantial at roughly $47.6M for the quarter, and cash burn continues at a pace of ~$158M over nine months. Watch for nuzefatide Phase 2 data updates in 2027 and the BT1702 trial initiation as key catalysts; the zelenectide program's deprioritization removes a potential near-term value driver.
Price Chart
Executive Summary
Bicycle Therapeutics reported Q3 2026 net loss of $10.5M ($-0.15 per share), significantly narrower than the $59.1M loss in Q3 2025, driven by a $34.1M collaboration revenue recognition from the terminated Bayer agreement and reduced R&D spending. The FDA granted Orphan Drug Designation for nuzefatide pevedotin in pancreatic cancer, and the company expects to initiate its first radioligand trial (BT1702) in 2H 2027. Cash burn continues with $469.9M remaining, providing runway into 2030.
Key Financial Metrics
Key Facts
- Net loss narrowed to $10.5M in Q3 2026 from $59.1M in Q3 2025, primarily due to $34.1M in collaboration revenue from the terminated Bayer agreement
- Cash and cash equivalents were $469.9M as of September 30, 2026, down from $628.1M at December 31, 2025
- FDA granted Orphan Drug Designation for nuzefatide pevedotin in pancreatic cancer in September 2026
- R&D expenses fell to $33.4M from $58.4M year-over-year due to reduced zelenectide spending and workforce reductions
- Collaboration revenue of $34.1M was recognized from the termination of the Bayer Consumer Care AG agreement
- Zelenectide pevedotin (Duravelo-2) deprioritized for internal development; survival data expected 2H 2027
- BT1702 radioligand trial initiation expected in 2H 2027
Financial Impact
Net loss improved by $48.6M year-over-year to $10.5M, but $34.1M of the improvement came from one-time collaboration revenue recognition
Risk Factors
- One-time collaboration revenue ($34.1M) from Bayer termination is non-recurring, masking the underlying operating burn
- Zelenectide program deprioritized for internal development, reducing pipeline optionality
- No consensus estimates provided for EPS or revenue; no beat/miss verdict possible
- Cash burn of ~$158M over nine months implies ~$210M annualized, though runway extends into 2030
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-119858 |
| Document: tm2628394d1_8k.htm | 0001104659-26-119858 |
| Document: 0001104659-26-119858-index-headers.html | 0001104659-26-119858 |
| Document: 0001104659-26-119858-index.html | 0001104659-26-119858 |
| Document: 0001104659-26-119858.txt | 0001104659-26-119858 |
| 8-K Data (Synthetic) | 0001104659-26-119858 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $3.82 | awaiting T+60 | awaiting T+60 | $3.66 (−4.19%) |
Oct 6, 2026 26d ago | 3/A | $3.73 | awaiting T+60 | awaiting T+60 | $3.66 (−1.88%) |
Jul 30, 2026 13w ago | 8-K | $4.01 $3.55 | ▼ −11.47% | ▼ −13.94% | $3.66 (−8.73%) |
May 21, 2026 23w ago | 8-K | $4.55 $3.99 | ▼ −12.31% | ▼ −15.50% | $3.66 (−19.56%) |
Apr 20, 2026 27w ago | 8-K | $5.29 $4.22 | ▼ −20.23% | ▼ −27.00% | $3.66 (−30.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers